Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression and treatment-free following a single infusion as early as second line Data suggest stronger immune fitness in earlier lines may be associated with longer progression free...
Hence then, the article about earlier use of carvykti demonstrated lasting treatment free remissions at 2 5 years in patients with relapsed or refractory multiple myeloma was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma )
Also on site :
- Blizzard conditions and tornadoes disrupt travel as winter brings frigid reality check back to the US
- Arrowhead Stadium Worker Reveals 'Beautifully Kind' Gesture From Taylor Swift During Chiefs' Christmas Day Game
- Samsung Plans to Bring Google Photos to Samsung AI TV Lineup, Helping Users Relive Their Favorite Memories on the Big Screen